Similar to our study, in a clinical study of 20 patients with metabolic syndrome, Kargiotis et al. [29] found that STAT monotherapy (10 mg/day) showed reduced liver steatosis on liver ultrasonography and biopsy within 12 months of treatment. Here, SOAT1 is linked to metabolic syndrome.